Intervention not reported
Adverse events Participants (n) reported serious adverse events · patients with osteoarthritis
1 finding from 1 review
- no estimate extracted1 study · 174 participantsGRADE not reported
Findings
What do systematic reviews say?
72 questions · 72 findings · 29 reviews
No studies found 13 · 18.1%GRADE not reported 8 · 11.1%Very low 21 · 29.2%Low 25 · 34.7%Moderate 5 · 6.9%High 0 · 0%
Intervention not reported
Adverse events Participants (n) reported serious adverse events · patients with treating osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate
Adverse events Participants (n) reported serious adverse events · patients with osteoarthritis
Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported serious adverse events compared with chondroitin sulphate (low certainty).
1 finding from 1 review
- RR 2.92 [0.31, 27.78]1 study · 357 participantsLow
IPV‐OPV vs IPV
Serious adverse events (≥ 1 symptom related to study drug or not) (Range of · infants
IPV‐OPV showed no clear difference in serious adverse events (≥ 1 symptom related to study drug or not)… compared with IPV (low certainty).
1 finding from 1 review
- Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis 2019 · Cochrane Headline outcomes onlyRR 0.92 [0.6, 1.43]2 studies · 1063 participantsLow
Fexofenadine 120 mg/d vs placebo (1‐week intervention)
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Fexofenadine 120 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (1‐week intervention) (moderate certainty).
1 finding from 1 review
- Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes onlyRR 1.05 [0.74, 1.5]1 study · 411 participantsModerate
Loratadine 10 mg vs placebo (4‐week intervention)
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Loratadine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
- Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes onlyRR 0.25 [0.01, 5.76]1 study · 28 participantsLow
Cetirizine 0.5 mg/kg/d vs placebo (18‐month intervention)
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · children with eczema
Cetirizine 0.5 mg/kg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (18‐month intervention) (moderate certainty).
1 finding from 1 review
- Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes onlyRR 0.68 [0.46, 1.01]1 study · 795 participantsModerate
Loratadine 10 mg vs placebo (2‐week intervention)
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
1 finding from 1 review
- Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes onlyno estimate extracted1 study · 73 participantsGRADE not reported
Cetirizine 10 mg/d vs placebo (4‐week intervention)
Primary outcome 2. Proportion of participants reporting adverse effects and serious adverse events throughout the study period · adults with eczema
Cetirizine 10 mg/d showed no clear difference in primary outcome 2. Proportion of participants reporting adverse… compared with placebo (4‐week intervention) (low certainty).
1 finding from 1 review
- Oral H1 antihistamines as ‘add‐on’ therapy to topical treatment for eczema 2019 · Cochrane Headline outcomes onlyRR 1.11 [0.5, 2.45]1 study · 84 participantsLow
Quinolone vs macrolides
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Macrolides vs tetracycline
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Quinolone vs tetracycline
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found